ARTVArtiva Biotherapeutics, Inc.

1. Sep 11, 2026On September 8, 2026, the Company held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”)Director or officer change · Form 8-K
2. Aug 6, 2026Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights.Earnings release · press release
3. Jul 22, 2026Artiva Biotherapeutics, Inc. (the “Company”) today announced that the expected date for the Company’s 2026 annual meeting of stockholders (the “Annual Meeting”) is September 8, 2026, which is more than 70 days after the one-year anniversary of the Company’s 2025 annual meeting of stockholders.Other event · Form 8-K
4. May 19, 2026Departure of Director On May 18, 2026, Diego Miralles, M.D. resigned as a member of the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), effective May 18, 2026, in connection with his appointment as President and Head of Research and Development of the Company as described below.Director or officer change · Form 8-K
5. May 8, 2026On May 8, 2026, Artiva Biotherapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and Cantor Fitzgerald & Co., as representatives of the several underwriters listed therein (collectively, the “Underwriters”), to issue and sell …Other event · Form 8-K
6. May 8, 2026ATM Suspension On May 8, 2026, the Company delivered written notice to Leerink Partners LLC (“Leerink”) that the Company has suspended and is not offering any shares of its common stock pursuant to the prospectus filed with the SEC on August 6, 2025, relating to the Sales Agreement, dated August 6, 2025 (the “Sales …Earnings release · Form 8-K
7. Mar 10, 2026Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights.Earnings release · press release
8. Feb 24, 2026On February 24, 2026, Artiva Biotherapeutics, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed Thad Huston as the Company's Chief Financial Officer.Director or officer change · Form 8-K
9. Feb 19, 2026On February 18, 2026, the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Elaine Sorg as a Class I director of the Company, with a term of office expiring at the Company’s 2028 annual …Director or officer change · Form 8-K
10. Dec 12, 2025On December 10-11, 2025, Artiva Biotherapeutics, Inc. (the Company) entered into Option for RSU Exchange Agreements (the Option for RSU Exchange Agreements) with a limited number of employees, including Fred Aslan, the Company’s President and Chief Executive Officer, and Jennifer Bush, the Company’s Chief Operating …Director or officer change · Form 8-K
11. Nov 12, 2025Initial Safety and Tolerability Data AlloNK is currently being explored in three ongoing Phase 1 and 2 clinical trials for the treatment of refractory rheumatoid arthritis (RA), Sjögren’s disease (SjD), idiopathic inflammatory myopathies, systemic sclerosis (SSc), and systemic lupus erythematosus (SLE)/lupus nephritis …Regulation FD disclosure · Form 8-K
12. Nov 12, 2025Artiva Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.